

PRESS RELEASE

For Immediate Release – March 12, 2010

Tranzyme Pharma's Clinical Results on Ulimorelin (TZP-101) Selected for Oral Presentation at the Distinguished Abstract Plenary Session of Digestive Disease Week 2010

RESEARCH TRIANGLE PARK, NC (March 12, 2010) – Tranzyme Pharma announced today that data from the Phase 2 clinical trial of ulimorelin (TZP-101) for the treatment of severe gastroparesis have been selected for an oral presentation at Digestive Disease Week (DDW) 2010 being held May 1-5, 2010 in New Orleans, LA.

Ulimorelin has previously shown the ability to enhance gastric emptying in patients with severe diabetic gastroparesis. The present analysis focused on the ability of this drug to relieve nausea and vomiting, which are the most serious and potentially life-threatening complications of this disorder. Consistent with its effects on gastric emptying, ulimorelin significantly reduced nausea and vomiting and improved overall symptomatology. These results further support ulimorelin's future role in the effective management of this debilitating condition.

"We are very pleased that the study results have been selected for presentation at this esteemed forum," said Gordana Kosutic, M.D., Vice President, Clinical and Regulatory Affairs for Tranzyme. "There are limited therapeutic options to treat this serious medical condition and the clinical community is eagerly awaiting a new safe and effective prokinetic therapy."

The presentation will be given by Richard McCallum, M.D., Professor and Founding Chairman of the Department of Internal Medicine, Texas Tech University Health Sciences Center at El Paso, and a Clinical Advisory Board member of Tranzyme, at the Neurogastroenterology and Motility Distinguished Abstract Plenary Session on Monday, May 3rd at 4:15pm EDT in Rooms 283-285 of the Ernest N. Morial Convention Center.

About Ulimorelin

Ulimorelin is an intravenous ghrelin agonist with potent prokinetic properties in clinical development for the treatment of gastrointestinal dysmotility conditions in acute care settings. Ulimorelin has been comprehensively studied in the management of two indications, severe gastroparesis and postoperative ileus (POI), and has the potential to

treat other conditions requiring administration of intravenous prokinetic agents in critical care settings. The safety and pharmacokinetic profiles of ulimorelin have been extensively characterized in healthy subjects and patients across multiple dose levels, and the GI prokinetic properties of the compound have been well established.

About Tranzyme Pharma

Tranzyme Pharma is a late stage biopharmaceutical company developing novel small molecule macrocyclic drugs for both acute care (hospital-based) and chronic indications with significant unmet medical need. The Company's pipeline is derived from its proprietary MATCH™ technology and targets two validated GPCR drug targets, ghrelin and motilin.

For more information on Tranzyme, please visit: www.tranzyme.com.

Contacts

Vipin K. Garg, PhD
President and CEO
(919) 313-4764

vgarg@tranzyme.com

Jennifer A. Filbey, PhD
VP, Business Development
(256) 417-8568

jfilbey@tranzyme.com

Susan S. Josselyn
Corporate Communications Manager
(919) 313-4761

sjosselyn@tranzyme.com